These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 35929954)

  • 21. Advocation and advancements of EPR effect theory in drug delivery science: A commentary.
    Hashida M
    J Control Release; 2022 Jun; 346():355-357. PubMed ID: 35483640
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Be Active or Not: the Relative Contribution of Active and Passive Tumor Targeting of Nanomaterials.
    Li R; Zheng K; Yuan C; Chen Z; Huang M
    Nanotheranostics; 2017; 1(4):346-357. PubMed ID: 29071198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. From Passive Targeting to Personalized Nanomedicine: Multidimensional Insights on Nanoparticles' Interaction with the Tumor Microenvironment.
    Sebak AA; El-Shenawy BM; El-Safy S; El-Shazly M
    Curr Pharm Biotechnol; 2021; 22(11):1444-1465. PubMed ID: 33308126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines.
    Greish K
    J Drug Target; 2007; 15(7-8):457-64. PubMed ID: 17671892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of next-generation macromolecular drugs based on the EPR effect: challenges and pitfalls.
    Nakamura H; Fang J; Maeda H
    Expert Opin Drug Deliv; 2015 Jan; 12(1):53-64. PubMed ID: 25425260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An EPR-Independent extravasation Strategy: Deformable leukocytes as vehicles for improved solid tumor therapy.
    Wu H; Li W; Hao M; Wang Y; Xue L; Ju C; Zhang C
    Adv Drug Deliv Rev; 2022 Aug; 187():114380. PubMed ID: 35662610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumors.
    Ojha T; Pathak V; Shi Y; Hennink WE; Moonen CTW; Storm G; Kiessling F; Lammers T
    Adv Drug Deliv Rev; 2017 Sep; 119():44-60. PubMed ID: 28697952
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strategies of engineering nanomedicines for tumor retention.
    Qian X; Xu X; Wu Y; Wang J; Li J; Chen S; Wen J; Li Y; Zhang Z
    J Control Release; 2022 Jun; 346():193-211. PubMed ID: 35447297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced permeability and retention effect-focused tumor-targeted nanomedicines: latest trends, obstacles and future perspective.
    Shekhar S; Chauhan M; Sonali ; Yadav B; Dutt R; Hu L; Muthu MS; Singh RP
    Nanomedicine (Lond); 2022 Aug; 17(18):1213-1216. PubMed ID: 36136592
    [No Abstract]   [Full Text] [Related]  

  • 30. Targeting endothelial permeability in the EPR effect.
    Lahooti B; Akwii RG; Zahra FT; Sajib MS; Lamprou M; Alobaida A; Lionakis MS; Mattheolabakis G; Mikelis CM
    J Control Release; 2023 Sep; 361():212-235. PubMed ID: 37517543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The development of novel tumor targeting delivery strategy].
    Gao HL; Jiang XG
    Yao Xue Xue Bao; 2016 Feb; 51(2):272-80. PubMed ID: 29856581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges.
    Khaitan D; Reddy PL; Ningaraj N
    Curr Clin Pharmacol; 2018; 13(2):110-119. PubMed ID: 29651960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Receptor-based targeting of engineered nanocarrier against solid tumors: Recent progress and challenges ahead.
    Akhter MH; Beg S; Tarique M; Malik A; Afaq S; Choudhry H; Hosawi S
    Biochim Biophys Acta Gen Subj; 2021 Feb; 1865(2):129777. PubMed ID: 33130062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in nano/micro systems for improved circulation stability, enhanced tumor targeting, penetration, and intracellular drug delivery: a review.
    Chan WJ; Li H
    Biomed Phys Eng Express; 2024 Jan; 10(2):. PubMed ID: 38086099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Destruction of tumor vasculature by vascular disrupting agents in overcoming the limitation of EPR effect.
    Liu Z; Zhang Y; Shen N; Sun J; Tang Z; Chen X
    Adv Drug Deliv Rev; 2022 Apr; 183():114138. PubMed ID: 35143895
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity.
    Maeda H
    Adv Drug Deliv Rev; 2015 Aug; 91():3-6. PubMed ID: 25579058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment.
    Park J; Choi Y; Chang H; Um W; Ryu JH; Kwon IC
    Theranostics; 2019; 9(26):8073-8090. PubMed ID: 31754382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nanomedicines in Diagnosis and Treatment of Cancer: An Update.
    Haider N; Fatima S; Taha M; Rizwanullah M; Firdous J; Ahmad R; Mazhar F; Khan MA
    Curr Pharm Des; 2020; 26(11):1216-1231. PubMed ID: 32188379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology.
    Prabhakar U; Maeda H; Jain RK; Sevick-Muraca EM; Zamboni W; Farokhzad OC; Barry ST; Gabizon A; Grodzinski P; Blakey DC
    Cancer Res; 2013 Apr; 73(8):2412-7. PubMed ID: 23423979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor-targeted nanomedicines for cancer theranostics.
    Arranja AG; Pathak V; Lammers T; Shi Y
    Pharmacol Res; 2017 Jan; 115():87-95. PubMed ID: 27865762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.